声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 2月25日，益丰药房跌0.37%，成交额2.14亿元。两融数据显示，当日益丰药房获融资买入额760.34万 元，融资偿还716.67万元，融资净买入43.67万元。截至2月25日，益丰药房融资融券余额合计8365.55万 元。 融资方面，益丰药房当日融资买入760.34万元。当前融资余额8259.75万元，占流通市值的0.28%，融资 余额低于近一年30%分位水平，处于低位。 分红方面，益丰药房A股上市后累计派现28.52亿元。近三年，累计派现19.46亿元。 机构持仓方面，截止2025年9月30日，益丰药房十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股1.99亿股，相比上期减少3819.35万股。南方中证500ETF（510500）位居第七大流通股 东，持股881.27万股，相比上期减少17.31万股。交银新成长混合（519736）位居第八大流通股东，持股 845.41 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 公司股东云南祥群投资有限公司及其一致行动人蓝波、深圳市畅思行实业发展有限公司、昆明南之图创 业投资合伙企业（有限合伙）、昆明云健宏创业投资合伙企业（有限合伙）、昆明春佳伟创业投资合伙 企业（有限合伙）、蓝抒悦、蓝心悦、者立纪、王宁、刘小涤、李梅、张燕飞、宋学金、吴丽敏，保证 向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 健之佳医药连锁集团股份有限公司（以下简称"公司"）实际控制人之一蓝波先生100%控股的云南祥群 投资有限公司（以下简称"云南祥群"）计划自2026年1月1日起6个月内，通过上海证券交易所交易系统 以集中竞价交易方式增持公司A股股份，增持总金额5,000万元，资金来源为自有资金及股票增持专项贷 款。具体增持计划内容详见公司于2026年1月1日在上海证券交易网站披露的《关于实际控制人的一致行 动人以自有资金及专项贷款增持公司股份计划的公告》（公告编号：2026-001）。 公司收到云南祥群《关于增持健之佳股份权益变动触及1%刻度的告知 ...

公司收到云南祥群《关于增持健之佳股份权益变动触及1%刻度的告知函》，其于2026年2月4日-2026年 2月24日，通过上海证券交易所交易系统以集中竞价的方式增持公司136.2313万股股份，占公司总股本 的0.88%；截至本公告披露日，云南祥群直接持有公司股份 1,518.0612万股，占公司总股本9.82%。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：605266 证券简称：健之佳 公告编号：2026-004 健之佳医药连锁集团股份有限公司 关于实际控制人的一致行动人权益变动触及1%刻度的提示性公告 公司股东云南祥群投资有限公司及其一致行动人蓝波、深圳市畅思行实业发展有限公司、昆明南之图创 业投资合伙企业（有限合伙）、昆明云健宏创业投资合伙企业（有限合伙）、昆明春佳伟创业投资合伙 企业（有限合伙）、蓝抒悦、蓝心悦、者立纪、王宁、刘小涤、李梅、张燕飞、宋学金、吴丽敏，保证 向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： ■ 健之佳医药连锁集团股份有限公司（以下简称"公司"）实际控制 ...

证券日报网讯2月12日，一心堂（002727）在互动平台回答投资者提问时表示，根据海南省商务厅发布 的公告，公司全资子公司海南鸿翔一心堂医药连锁有限公司获得海南自由贸易港岛内居民消费的"零关 税"进境商品经营资格。 ...

南财智讯1月29日电，漱玉平民发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 8000万元—12000万元，同比预计扭亏；预计2025年全年归属于上市公司股东的扣除非经常性损益的净 利润为1350万元—2000万元，同比预增106.82%—110.10%。业绩变动原因说明：1、报告期内，公司聚 焦核心品类优化商品策略，同步推动核心门店业态与场景升级，多种举措带动整体毛利率实现同比提 升，公司盈利能力呈现稳步回升的良好态势。同时，报告期内公司持续优化门店网络布局，降租控费， 深度应用数字化工具，降低费销比，公司整体运营周转效率与精细化管理水平显著提升。2、报告期 内，依据前期签署的业绩承诺相关协议，公司确认青岛春天之星医药连锁有限公司标的业绩承诺补偿款 合计金额1.27亿元，该事项增加了公司非经常性损益，对利润产生正向影响。 ...

Group 1 - The Guangdong Provincial People's Congress and the Chinese People's Political Consultative Conference are convening, focusing on local economic development and community issues [7][8]. - Representatives are promoting local specialties to boost consumption, with suggestions for enhancing the market for unique products like Zijin cicada tea and local candies [8][9]. - There is a strong emphasis on agricultural modernization and resource management, with proposals for establishing seed resource cultivation bases and improving food reserve efficiency [9]. Group 2 - Urban development is shifting from rapid expansion to quality improvement, with a focus on renovating old neighborhoods and factories [10]. - Suggestions include innovative financing products to support the renovation of old residential areas and allowing historical factories to undergo self-renovation under urban planning [10]. - The importance of the private economy in driving industrial upgrades and technological innovation is highlighted, with discussions on extending loan terms for small and medium enterprises to support their growth [11]. Group 3 - The internationalization of Guangdong enterprises is a key concern, with recommendations to leverage regional resources and successful experiences from other provinces to enhance global competitiveness [11].

Group 1 - The core issue of gut health is highlighted as a crucial foundation for overall health and reducing the risk of chronic diseases, with a significant prevalence of chronic constipation in adults in China, particularly among the elderly [1] - The prevalence of chronic constipation among adults in China is approximately 4%-6%, increasing significantly with age, reaching up to 22% in individuals over 60 years old [1] Group 2 - A public welfare science popularization event focused on gut health was launched in Nanning on January 21, 2026, aiming to promote the "prevention first" concept in response to the "Healthy China" strategy [3] - The event attracted hundreds of community residents despite inclement weather, demonstrating strong community engagement [3] Group 3 - The event was co-hosted by Family Doctor Online and the Chinese Medicine Culture Research Association, with support from local pharmacy and pharmaceutical companies, aiming to enhance health awareness and provide quality health resources [3][5] - The general manager of Dacare Pharmacy emphasized the company's commitment to community health and the importance of integrating professional medical resources into residents' daily lives [5] Group 4 - The national KA director of Nanjing Zhengda Tianqing Pharmaceutical Company highlighted the importance of proactive health management as a corporate social responsibility, aiming to make health knowledge accessible to residents [7] - The event's launch symbolizes a collaborative effort to improve community health literacy and build healthier communities [9] Group 5 - A medical expert conducted a lecture on common gut issues, emphasizing the importance of balanced diet and regular exercise for maintaining gut health, with an interactive Q&A session that engaged community residents [11][13] - The event's representatives discussed the long-term significance of the initiative, focusing on community health promotion and transforming health knowledge into actionable steps for residents [15] Group 6 - The successful launch of the Nanning event marks the further advancement of the nationwide "Gut Health for All" public welfare initiative, which has previously been held in multiple provinces and cities [16] - Nanjing Zhengda Tianqing plans to continue collaborating with partners to expand the initiative to more cities, aiming to spread scientific health knowledge to broader communities [16]

Group 1 - Company approved the use of up to RMB 2.5 billion of idle funds for cash management, including investments in fixed-income products and time deposits [1][2] - The cash management program allows for rolling use of funds within the approved limit, with the chairman authorized to implement related matters [1] - Recent cash management activities have resulted in the maturity and recovery of certain products [2] Group 2 - Company agreed to provide a guarantee for its wholly-owned subsidiary, Hainan Hongxiang Yixintang Pharmaceutical Chain Co., Ltd., to apply for a credit limit of RMB 1.408 billion from banks [5][6] - A maximum guarantee amount of RMB 30 million has been established under a joint liability guarantee contract with Shanghai Pudong Development Bank [7][8] - The total amount of guarantees provided by the company and its subsidiaries is RMB 1.34227 billion, with a current balance of RMB 900.898 million, representing 11.77% of the company's audited net assets for 2024 [9][10]

Group 1 - The main subject of the increase is Yunnan Xiangqun Investment Co., Ltd., which is 100% controlled by Lan Bo, one of the actual controllers of the company, holding 13,818,299 shares, accounting for 8.9414% of the total share capital [2] - The increase plan involves Yunnan Xiangqun intending to increase its holdings of the company's A-shares by a total amount of 50 million yuan within six months through the Shanghai Stock Exchange trading system, using its own funds and a special loan for stock purchases [2] - The increase plan will not trigger a mandatory tender offer and will not lead to changes in the company's controlling shareholder or actual controller [2] Group 2 - The increase plan is in compliance with relevant laws and regulations, including the Securities Law of the People's Republic of China and the Management Measures for the Acquisition of Listed Companies [5] - The increase behavior will not affect the company's listing status or lead to changes in the distribution of the company's equity that would jeopardize listing conditions [5] - The company will continuously monitor the situation regarding the increase of shares by the actual controller and its concerted actors, and will fulfill its information disclosure obligations in a timely manner [5]

Group 1 - The core point of the article is that Yixin Tang's wholly-owned subsidiary, Hainan Hongxiang Yixin Tang Pharmaceutical Chain Co., Ltd., acquired state-owned industrial land use rights through a bidding process in December 2020, covering an area of 69,673.04 square meters [1] Group 2 - The acquisition of land use rights was conducted via a public auction for state-owned land and buildings [1] - The relevant announcement regarding this acquisition was disclosed by the company on December 3, 2020, on the Giant Tide Information Network [1]